news
Mission Therapeutics receives $500k grant for Parkinson’s research
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
List view / Grid view
MISSION Therapeutics
news
Mission Therapeutics appoints Colin Goddard as Chairman
Mission Therapeutics have appointed Dr Colin Goddard as non-executive Chairman, effective January 1st 2017.
news
MISSION Therapeutics raises £60m to advance DUB inhibitors
2 February 2016 | By Victoria White
The £60 million enables the company to maximise the potential of its DUB platform and advance a series of DUB inhibitors...
news
MISSION Therapeutics receives funding for DUB cancer programme
24 September 2015 | By Victoria White
Deubiquitylating enzymes (DUBs) are involved in multiple cellular processes, including DNA damage and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs...
news
MISSION Therapeutics appoints Dr Michael Koslowski as Chief Medical Officer
1 September 2015 | By Nick Jackson
Dr Koslowski brings over 15 years’ experience across biopharmaceutical research and development, specialising in drug target discovery and clinical validation...
news
Round 8 of Biomedical Catalyst awards announced
10 August 2015 | By Charlotte Batchelor, Drug Target Review
Twelve new treatments, diagnostics and medical technologies will receive funding from the eighth round of the successful Biomedical Catalyst (BMC)...
news
MISSION Therapeutics appoints Paul Wallace as Chief Business Officer
19 March 2015 | By Victoria White
MISSION Therapeutics announces the appointment of Paul Wallace PhD as Chief Business Officer...